Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AML-BFM 2012: clinical trial for the treatment of acute myeloid leukemia in children and adolescents - an open prospective randomized phase III trial

Trial Profile

AML-BFM 2012: clinical trial for the treatment of acute myeloid leukemia in children and adolescents - an open prospective randomized phase III trial

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2019

At a glance

  • Drugs Clofarabine (Primary) ; Etoposide (Primary) ; Cytarabine; Daunorubicin; Methotrexate; Mitoxantrone; Prednisolone; Sorafenib; Tioguanine
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms AML-BFM 2012
  • Most Recent Events

    • 19 Apr 2019 The trial has been discontinued in austria.
    • 11 Apr 2017 Status changed from recruiting to completed.
    • 03 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top